A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- Biological: efgartigimod PH20 SC in stage BOther: placebo in stage B
- Registration Number
- NCT04281472
- Lead Sponsor
- argenx
- Brief Summary
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 322
-
Ability to understand the requirements of the trial, provide written informed consent (include consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits)
-
Male or female patient aged 18 years or older, at the time of signing the informed consent.
-
Diagnosed with probable or definite CIDP according to criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010), progressing or relapsing forms.
-
CIDP Disease Activity Status (CDAS) score ≥2 at screening.
-
INCAT score ≥2 at the first run-in visit (for patients entering run-in) or stage A baseline (for treatment-naïve patients with documented evidence for worsening on the total adjusted INCAT disability score within 3 months prior to screening). Patients with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score; for patients with an INCAT score of ≥3 at trial entry, there are no specific requirements for arm or leg scores.
-
Fulfilling any of the following treatment conditions:
- Currently treated with pulsed corticosteroids, oral corticosteroids equivalent to prednisolone/prednisone ≤10mg/day, and/or IVIg or SCIg, if this treatment has been started within the last 5 years before screening, and the patient is willing to discontinue this treatment at the first run-in visit; or
- Without previous treatment (treatment-naive); or
- Treatment with corticosteroids and/or IVIg or SCIg discontinued at least 6 months prior to screening Note: Patients not treated with monthly or daily corticosteroids, IVIg or SCIg for at least 6 months prior to screening are considered as equal to treatment-naïve patients.
-
Women of childbearing potential who have a negative pregnancy test at screening and a negative urine pregnancy test up to Stage A baseline.
-
Women of childbearing potential must use an acceptable method of contraception from signing the ICF until the date of the last dose of IMP
-
Pure sensory atypical CIDP (EFNS/PNS definition).
-
Polyneuropathy of other causes, including the following: Multifocal motor neuropathy; Monoclonal gammopathy of uncertain significance with anti-myelin associated, glycoprotein immunoglobulin M (IgM) antibodies; Hereditary demyelinating neuropathy; Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy.
-
Any other disease that could better explain the patient's signs and symptoms.
-
Any history of myelopathy or evidence of central demyelination.
-
Current or past history (within 12 months of screening) of alcohol, drug or medication abuse.
-
Severe psychiatric disorder (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation that in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol.
-
Patients with clinically significant active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including patients who test positive for an active viral infection at screening with: Active Hepatitis B Virus (HBV): serologic panel test results indicative of an active (acute or chronic) infection; Active Hepatitis C Virus (HCV): serology positive for HCV-Ab; Human Immunodeficiency Virus (HIV) positive serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining condition or with a cluster of differentiation 4 (CD4) count ≤200 cells/mm3.
-
Total IgG level <6 g/L at screening.
-
Treatment with the following: Within 3 months (or 5 half-lives of the drug, whichever is longer) before screening: plasma exchange or immunoadsorption, any concomitant Fc-containing therapeutic agents or other biological, or any other investigational product; Within 6 months before screening: rituximab, alemtuzumab, any other monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, methotrexate, azathioprine, mycophenolate, any other immunomodulating or immunosuppressive medications, and oral daily corticosteroids >10 mg/day. Note: Patients using IVIg, SCIg, pulsed corticosteroids, and oral daily corticosteroids ≤10 mg/day can be included.
Patients who (intend to) use prohibited medications and therapies (see protocol) during the trial.
-
Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after last IMP administration.
-
Patients with any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of CIDP.
-
Patients who received a live-attenuated vaccine fewer than 28 days before screening. Receiving an inactivated, sub-unit, polysaccharide, or conjugate vaccine any time before screening is not exclusionary.
-
Patients who have a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first IMP administration. Patients with the following cancer can be included anytime: Adequately treated basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, or Incidental histological finding of Prostate cancer (TNM [tumor, nodes, and metastases classification] stage T1a or T1b).
-
Patients who previously participated in a trial with efgartigimod and have received at least one administration of IMP.
-
Patients with known medical history of hypersensitivity to any of the ingredients of IMP.
-
Patients with clinical evidence of other significant serious disease or patients who underwent a recent or have a planned major surgery, or any other reason which could confound the results of the trial or put the patient at undue risk.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description efgartigimod PH20 SC efgartigimod PH20 SC in stage B patients receiving efgartigimod PH20 SC in both stage A as stage B Placebo efgartigimod PH20 SC in stage B patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B Placebo placebo in stage B patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B
- Primary Outcome Measures
Name Time Method Stage B: Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline Up to 48 weeks during the randomized placebo-controlled stage B Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) Up to 12 weeks during the open-label stage A
- Secondary Outcome Measures
Name Time Method Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Medical Research Council (MRC) Sum Score Up to 12 weeks during the open-label stage A The Medical Research Council (MRC) Sum scores range from 0 to 60 with a lower score indicating greater muscle weakness.
Stage B: Pre-dosing Efgartigimod Serum Concentrations Over Time Up to 48 weeks during the randomized placebo-controlled stage B Stage B: Percent Changes of Serum IgG Levels Over Time Up to 48 weeks during the randomized placebo-controlled stage B Stage B: Changes From Stage B Baseline to Last Assessment in Stage B, in EQ-5D-5L Visual Analog Scale (VAS) Over Time Up to 48 weeks during the randomized placebo-controlled stage B Scores range from 0-100 with 100 indicating the best health state. Therefore, positive changes indicate higher health-related quality of life reported by the patient.
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI) Up to 12 weeks during the open-label stage A Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in I-RODS Disability Scores Up to 12 weeks during the open-label stage A The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability.
Stage B: Time to CIDP Disease Progression Up to 48 weeks during the randomized placebo-controlled stage B Time to chronic inflammatory demyelinating polyneuropathy (CIDP) disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric.
Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in TUG Score Up to 48 weeks during the randomized placebo-controlled stage B The Timed Up and Go (TUG) score is calculated as the number of seconds needed to complete a series of actions. The longer time needed to complete this test (expressed in seconds) indicates lower mobility.
Stage A: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events Up to 12 weeks during the open-label stage A Treatment-emergent (serious) AEs expressed in number of events/100 PYFU (participant years of follow-up)
Stage A: Number of Participants With Binding Antidrug Antibodies (ADA) Towards Efgartigimod or Antibodies (Ab) Against rHuPH20 and Neutralizing Antibodies (NAb) Against Efgartigimod and/or rHuPH20 Up to 12 weeks during the open-label stage A Stage A: Changes From Stage A Baseline to Last Assessment in Stage A, in EQ-5D-5L Visual Analog Scale (VAS) Over Time Up to 12 weeks during the open-label stage A Scores range from 0-100 with 100 indicating the best health state. Therefore, positive changes indicate higher health-related quality of life reported by the patient.
Stage B: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events Up to 48 weeks during the randomized placebo-controlled stage B Treatment-emergent (serious) AEs expressed in number of events/100 PYFU (participant years of follow-up)
Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Adjusted INCAT Score Up to 12 weeks during the open-label stage A Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability.
Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Mean Grip Strength Up to 12 weeks during the open-label stage A This is measured with a handheld device called a vigometer
Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline Up to 48 weeks during the randomized placebo-controlled stage B Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in Adjusted INCAT Score Up to 48 weeks during the randomized placebo-controlled stage B Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability.
Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in MRC Sum Score Up to 48 weeks during the randomized placebo-controlled stage B The Medical Research Council (MRC) Sum scores range from 0 to 60 with a lower score indicating greater muscle weakness.
Stage B: Number of Participants With Binding Antidrug Antibodies (ADA) Towards Efgartigimod or Antibodies (Ab) Against rHuPH20 and Neutralizing Antibodies (NAb) Against Efgartigimod and/or rHuPH20 Up to 48 weeks during the randomized placebo-controlled stage B Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in TUG Score Up to 12 weeks during the open-label stage A The Timed Up and Go (TUG) score is calculated as the number of seconds needed to complete a series of actions. The longer time needed to complete this test (expressed in seconds) indicates lower mobility.
Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time Up to 13 weeks during the open-label stage A (12 weeks + optional 1 additional week to confirm evidence of clinical improvement (ECI)) Stage A: Percent Changes From Stage A Baseline of Serum IgG Levels Over Time Up to 13 weeks during the open-label stage A (12 weeks + optional 1 additional week to confirm evidence of clinical improvement (ECI)) Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in 24-item I-RODS Disability Score Up to 48 weeks during the randomized placebo-controlled stage B The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability.
Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in Mean Grip Strength Up to 48 weeks during the randomized placebo-controlled stage B This is measured with a handheld device called a vigometer
Stage B: Time to 10% Decrease in the 24-item I-RODS Up to 48 weeks during the randomized placebo-controlled stage B The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability.
Trial Locations
- Locations (212)
Investigator site 0010077
🇺🇸Durham, North Carolina, United States
Investigator site 0860038
🇨🇳Fuzhou, China
Investigator site 0860031
🇨🇳Jinan, China
Investigator Site 0860040
🇨🇳Nanchang, China
Investigator site 0860051
🇨🇳Nanchang, China
Investigator site 0860028
🇨🇳Shangai, China
Investigator site 0860047
🇨🇳Shanghai, China
Investigator site 0860029
🇨🇳Wuhan, China
Investigator site 0860034
🇨🇳Wuhan, China
Investigator site 0860048
🇨🇳Xi'an, China
Investigator site 0010055
🇺🇸Scottsdale, Arizona, United States
Investigator Site 0010032
🇺🇸Carlsbad, California, United States
Investigator site 0010190
🇺🇸Pomona, California, United States
Investigator site 0010004
🇺🇸Orange, California, United States
Investigator site 0010160
🇺🇸Rancho Mirage, California, United States
Investigator site 0010057
🇺🇸Centennial, Colorado, United States
Investigator site 0010026
🇺🇸Houston, Texas, United States
Investigator site 0010023
🇺🇸Jacksonville, Florida, United States
Investigator site 0010144
🇺🇸Coral Springs, Florida, United States
Investigator site 0010072
🇺🇸Boca Raton, Florida, United States
Investigator Site 0010068
🇺🇸Maitland, Florida, United States
Investigator site 0010059
🇺🇸Miami, Florida, United States
Investigator site 0010172
🇺🇸Ormond Beach, Florida, United States
Investigator site 0010125
🇺🇸Augusta, Georgia, United States
Investigator site 0010015
🇺🇸Fairway, Kansas, United States
Investigator site 0010052
🇺🇸Minneapolis, Minnesota, United States
Investigator site 0010063
🇺🇸East Lansing, Michigan, United States
Investigator site 0010070
🇺🇸New Brunswick, New Jersey, United States
Investigator site 0010028
🇺🇸Columbia, Missouri, United States
Investigator site 0010069
🇺🇸New York, New York, United States
Investigator site 0010168
🇺🇸New York, New York, United States
Investigator site 0010074
🇺🇸New York, New York, United States
Investigator site 0010191
🇺🇸New York, New York, United States
Investigator site 0010075
🇺🇸Patchogue, New York, United States
Investigator site 0010064
🇺🇸Columbus, Ohio, United States
Investigator site 0010047
🇺🇸Philadelphia, Pennsylvania, United States
Investigator site 0010007
🇺🇸Charlottesville, Virginia, United States
Investigator site 0010067
🇺🇸Pittsburgh, Pennsylvania, United States
Investigator site 0010009
🇺🇸San Antonio, Texas, United States
Investigator site 0010076
🇺🇸Burlington, Vermont, United States
Investigator site 0430007
🇦🇹Innsbruck, Austria
Investigator site 0430006
🇦🇹Salzburg, Austria
Investigator site 0320019
🇧🇪Brussel, Belgium
Investigator site 0320016
🇧🇪Edegem, Belgium
Investigator site 0320017
🇧🇪Brussel, Belgium
Investigator site 0320009
🇧🇪Leuven, Belgium
Investigator site 0320024
🇧🇪Liège, Belgium
Investigator site 0320022
🇧🇪Woluwe-Saint-Lambert, Belgium
Investigator site 3590007
🇧🇬Pleven, Bulgaria
Investigator site 3590008
🇧🇬Sofia, Bulgaria
Investigator site 0860033
🇨🇳Beijing, China
Investigator site 3590009
🇧🇬Sofia, Bulgaria
Investigator site 0860030
🇨🇳Changchun, China
Investigator site 0860036
🇨🇳Chengdu, China
Investigator site 0860041
🇨🇳Changsha, China
Investigator site 0860049
🇨🇳Chifeng, China
Investigator site 0860050
🇨🇳Guanzhou, China
Investigator site 0860045
🇨🇳Guiyang, China
Investigator site 0860032
🇨🇳Guanzhou, China
Investigator site 0860046
🇨🇳Hangzhou, China
Investigator site 0860035
🇨🇳Hanzhou, China
Investigator site 0860063
🇨🇳Jining, China
Investigator site 0860044
🇨🇳Nanchang, China
Investigator site 0860043
🇨🇳Nanjing, China
Investigator site 0860052
🇨🇳Shanghai, China
Investigator site 0860042
🇨🇳Taiyuan, China
Investigator site 0860037
🇨🇳Xi'an, China
Investigator site 0860054
🇨🇳Xiangyang, China
Investigator site 0450003
🇩🇰Odense, Denmark
Investigator site 0450002
🇩🇰Aarhus, Denmark
Investigator site 0330034
🇫🇷Angers, France
Investigator site 0330013
🇫🇷Bordeaux, France
Investigator site 0330033
🇫🇷Clermont-Ferrand, France
Investigator site 0330025
🇫🇷Garches, France
Investigator site 0330023
🇫🇷Le Kremlin-Bicêtre, France
Investigator site 0330024
🇫🇷Limoges, France
Investigator site 0330021
🇫🇷Nice, France
Investigator site 0330035
🇫🇷Paris, France
Investigator site 0330022
🇫🇷Nantes, France
Investigator site 0330020
🇫🇷Strasbourg, France
Investigator site 9950020
🇬🇪Kutaisi, Georgia
Investigator Site 9950002
🇬🇪Tbilisi, Georgia
Investigator Site 9950003
🇬🇪Tbilisi, Georgia
Investigator site 0490018
🇩🇪Berlin, Germany
Investigator site 0490045
🇩🇪Essen, Germany
Investigator site 0490021
🇩🇪Göttingen, Germany
Investigator site 0490016
🇩🇪Kiel, Germany
Investigator site 0490014
🇩🇪Hannover, Germany
Investigator site 0490020
🇩🇪Leipzig, Germany
Investigator site 0490013
🇩🇪Köln, Germany
Investigator site 0490015
🇩🇪Regensburg, Germany
Investigator site 0360017
🇭🇺Budapest, Hungary
Investigator site 0490019
🇩🇪Potsdam, Germany
Investigator site 0360018
🇭🇺Kistarcsa, Hungary
Investigator site 9720006
🇮🇱H̱olon, Israel
Investigator site 9720005
🇮🇱Ramat Gan, Israel
Investigator site 0390022
🇮🇹Brescia, Italy
Investigator site 0390029
🇮🇹Firenze, Italy
Investigator site 9720004
🇮🇱Tel Aviv, Israel
Investigator site 0390024
🇮🇹Genova, Italy
Investigator site 0390027
🇮🇹Messina, Italy
Investigator site 0390003
🇮🇹Milano, Italy
Investigator site 0390007
🇮🇹Napoli, Italy
Investigator site 0390026
🇮🇹Milano, Italy
Investigator site 0390023
🇮🇹Pisa, Italy
Investigator site 0390042
🇮🇹Torino, Italy
Investigator site 0390008
🇮🇹Roma, Italy
Investigator site 0390028
🇮🇹Siena, Italy
Investigator site 0810002
🇯🇵Chiba, Japan
Investigator site 0810035
🇯🇵Bunkyō-Ku, Japan
Investigator site 0810034
🇯🇵Chuo Ku, Japan
Investigator site 0810031
🇯🇵Fukuoka, Japan
Investigator site 0810058
🇯🇵Hiroshima, Japan
Investigator site 0810030
🇯🇵Fuchū, Japan
Investigator site 0810066
🇯🇵Hakodate, Japan
Investigator site 0810065
🇯🇵Ginowan, Japan
Investigator site 0810036
🇯🇵Itabashi, Japan
Investigator site 0810026
🇯🇵Kodaira, Japan
Investigator site 0810029
🇯🇵Kawaguchi, Japan
Investigator site 0810062
🇯🇵Kawasaki, Japan
Investigator site 0810061
🇯🇵Kyoto, Japan
Investigator site 0810027
🇯🇵Mibu, Japan
Investigator site 0810003
🇯🇵Osaka, Japan
Investigator site 0810028
🇯🇵Sagamihara, Japan
Investigator site 0810007
🇯🇵Osaka, Japan
Investigator site 0810037
🇯🇵Shinjuku-Ku, Japan
Investigator site 0810033
🇯🇵Sapporo, Japan
Investigator site 3710001
🇱🇻Riga, Latvia
Investigator site 0810063
🇯🇵Suita, Japan
Investigator site 0310010
🇳🇱Amsterdam, Netherlands
Investigator site 0310011
🇳🇱Rotterdam, Netherlands
Investigator site 0810060
🇯🇵Yokohama, Japan
Investigator site 0810064
🇯🇵Tokushima, Japan
Investigator site 0480019
🇵🇱Białystok, Poland
Investigator site 0480023
🇵🇱Katowice, Poland
Investigator site 0480024
🇵🇱Kraków, Poland
Investigator site 0480017
🇵🇱Kraków, Poland
Investigator site 0480018
🇵🇱Lublin, Poland
Investigator site 0480022
🇵🇱Warsaw, Poland
Investigator site 0480020
🇵🇱Łódź, Poland
Investigation site 0400002
🇷🇴Braşov, Romania
Investigator site 0070020
🇷🇺Moscow, Russian Federation
Investigator site 0070023
🇷🇺Kazan, Russian Federation
Investigator site 0070016
🇷🇺Moscow, Russian Federation
Investigator site 0070017
🇷🇺Kazan, Russian Federation
Investigator site 0070018
🇷🇺Perm, Russian Federation
Investigator site 0070019
🇷🇺Rostov-on-Don, Russian Federation
Investigator site 0070021
🇷🇺Saransk, Russian Federation
Investigator site 0340020
🇪🇸Alicante, Spain
Investigator site 3810003
🇷🇸Belgrad, Serbia
Investigator site 3810004
🇷🇸Kragujevac, Serbia
Investigator site 0340021
🇪🇸Badalona, Spain
Investigator site 0340038
🇪🇸Barcelona, Spain
Investigator site 0340019
🇪🇸Córdoba, Spain
Investigator site 0340018
🇪🇸Madrid, Spain
Investigator site 0340017
🇪🇸Madrid, Spain
Investigator site 8860014
🇨🇳Kaohsiung, Taiwan
Investigator site 0340016
🇪🇸Sevilla, Spain
Investigator site 8860011
🇨🇳Taipei, Taiwan
Investigator site 0900023
🇹🇷Istanbul, Turkey
Investigator site 8860016
🇨🇳Taipei, Taiwan
Investigator site 0900025
🇹🇷Bursa, Turkey
Investigator site 0900024
🇹🇷Sarıçam, Turkey
Investigator site 0900021
🇹🇷İzmir, Turkey
Investigator site 3800012
🇺🇦Dnipro, Ukraine
Investigator site 3800014
🇺🇦Dnipropetrovs'k, Ukraine
Investigator site 3800010
🇺🇦Ivano-Frankivs'k, Ukraine
Investigator site 3800015
🇺🇦Vinnytsia, Ukraine
Investigator site 380008
🇺🇦Luts'k, Ukraine
Investigator site 3800013
🇺🇦Kyiv, Ukraine
Investigator site 380009
🇺🇦Vinnytsia, Ukraine
Investigator site 3800011
🇺🇦Zaporizhzhya, Ukraine
Investigator site 0440017
🇬🇧Glasgow, United Kingdom
Investigator site 0440015
🇬🇧Inverness, United Kingdom
Investigator site 0440019
🇬🇧Stoke-on-Trent, United Kingdom
Investigator site 0440026
🇬🇧London, United Kingdom
Investigator site 0440016
🇬🇧Oxford, United Kingdom
Investigator site 0440018
🇬🇧Sheffield, United Kingdom
Investigator site 0440028
🇬🇧Tooting, United Kingdom
Investigator site 3590005
🇧🇬Sofia, Bulgaria
Investigator site 4200010
🇨🇿Hradec Králové, Czechia
Investigator site 0450001
🇩🇰Copenhagen, Denmark
Investigator site 0010051
🇺🇸Cincinnati, Ohio, United States
Investigator site 0070014
🇷🇺Saint Petersburg, Russian Federation
Investigator site 0490044
🇩🇪Bochum, Germany
Investigator site 0430009
🇦🇹Graz, Austria
Investigator site 0490017
🇩🇪Berlin, Germany
Investigator site 0810032
🇯🇵Nagoya, Japan
Investigator site 0900022
🇹🇷Samsun, Turkey
Investigator Site 9950004
🇬🇪Tbilisi, Georgia
Investigator site 0400003
🇷🇴Timişoara, Romania
Investigator site 0400001
🇷🇴Bucharest, Romania
Investigator site 8860013
🇨🇳Tainan, Taiwan
Investigator site 0400004
🇷🇴Constanţa, Romania
Investigator site 8860015
🇨🇳Taichung, Taiwan
Investigator site 0430005
🇦🇹Wien, Austria
Investigator site 8860017
🇨🇳Taoyuan, Taiwan
Investigator site 0430008
🇦🇹Linz, Austria
Investigator site 9950005
🇬🇪Tbilisi, Georgia
Investigator site 3810001
🇷🇸Belgrad, Serbia
Investigator site 8860012
🇨🇳Taipei, Taiwan
Investigator site 0010071
🇺🇸San Francisco, California, United States
Investigator site 0010065
🇺🇸Birmingham, Alabama, United States
Investigator site 0010013
🇺🇸Phoenix, Arizona, United States
Investigator site 0010006
🇺🇸Tampa, Florida, United States
Investigator site 0010050
🇺🇸Orlando, Florida, United States
Investigator site 0010014
🇺🇸Detroit, Michigan, United States
Investigator site 0010003
🇺🇸Chapel Hill, North Carolina, United States
Investigator site 0010066
🇺🇸Austin, Texas, United States
Investigator site 0010061
🇺🇸Richmond, Virginia, United States
Investigator site 0010147
🇺🇸Lexington, Kentucky, United States
Investigator site 0010011
🇺🇸Iowa City, Iowa, United States